NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $77,177 | -41.3% | 18,916 | -27.7% | 0.04% | -39.1% |
| Q4 2022 | $131,429 | +20.6% | 26,181 | +214.4% | 0.07% | +60.5% |
| Q3 2022 | $109,000 | +2.8% | 8,327 | +0.8% | 0.04% | +10.3% |
| Q2 2022 | $106,000 | -20.9% | 8,263 | -5.9% | 0.04% | -35.0% |
| Q1 2022 | $134,000 | -18.8% | 8,782 | -5.6% | 0.06% | -3.2% |
| Q4 2021 | $165,000 | -28.3% | 9,301 | -14.9% | 0.06% | -38.6% |
| Q3 2021 | $230,000 | +1.3% | 10,924 | -5.0% | 0.10% | +8.6% |
| Q2 2021 | $227,000 | -28.2% | 11,501 | +5.8% | 0.09% | -30.1% |
| Q1 2021 | $316,000 | -2.5% | 10,874 | +1.8% | 0.13% | -0.7% |
| Q4 2020 | $324,000 | +36.7% | 10,685 | -28.2% | 0.13% | +8.1% |
| Q3 2020 | $237,000 | -29.0% | 14,880 | -12.0% | 0.12% | -21.5% |
| Q2 2020 | $334,000 | – | 16,913 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |